Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Real World Analysis from a Single Center (ATC 2026) - Jun 17, 2026 - Abstract #Abstract D165; Pres time: Jun 23, 2026; 02:30 PM - 03:30 PM; Location: Exhibit Hall; "In this retrospective real-world cohort study LET for CMV primary prophylaxis is effective and well tolerated. LET prophylaxis is more likely to be completed for the intended duration compared with VGCV prophylaxis; LET is associated with less myelosuppressive toxicity and reduced HCRU. Larger studies are needed to definitively evaluate the impact of LET on rejection rates and transplant outcomes."
Clinical • Real-world • Real-world evidence • Cytomegalovirus Infection • Hematological Disorders • Leukopenia • Neutropenia • Transplantation
|
|
M. Jorgenson 1; J. Descourouez 1; G. Leverson 2; W. Rose 2; A. Beyer 3; D. Al-Adra 2
|